Free Trial

Fate Therapeutics Q4 2024 Earnings Report

Fate Therapeutics logo
$0.92 -0.05 (-4.74%)
As of 03/18/2025 04:00 PM Eastern

Fate Therapeutics EPS Results

Actual EPS
-$0.31
Consensus EPS
-$0.44
Beat/Miss
Beat by +$0.13
One Year Ago EPS
N/A

Fate Therapeutics Revenue Results

Actual Revenue
$1.86 million
Expected Revenue
$1.57 million
Beat/Miss
Beat by +$291.00 thousand
YoY Revenue Growth
N/A

Fate Therapeutics Announcement Details

Quarter
Q4 2024
Time
Before Market Opens

Conference Call Resources

Remove Ads

Fate Therapeutics Earnings Headlines

Your Wealth is Under Attack
Have you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's coming next. But here's the truth… This is just the beginning. Trump has made it clear his tariffs are coming, and that the market will get worse before it gets better. Luckily, our FREE Presidential Transition Guide details exactly what will happen in the next 100 days, and how to protect your hard-earned savings during these times. Don't wait for the next crash to wipe you out. Act now.
Fate Therapeutics price target lowered to $2.50 from $3 at BofA
Q1 EPS Estimates for Fate Therapeutics Increased by Wedbush
See More Fate Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Fate Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Fate Therapeutics and other key companies, straight to your email.

About Fate Therapeutics

Fate Therapeutics (NASDAQ:FATE), a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

View Fate Therapeutics Profile

More Earnings Resources from MarketBeat